NZ631118A - Methods for treating nasal polyposis by administering an il-4r antagonist - Google Patents

Methods for treating nasal polyposis by administering an il-4r antagonist

Info

Publication number
NZ631118A
NZ631118A NZ631118A NZ63111814A NZ631118A NZ 631118 A NZ631118 A NZ 631118A NZ 631118 A NZ631118 A NZ 631118A NZ 63111814 A NZ63111814 A NZ 63111814A NZ 631118 A NZ631118 A NZ 631118A
Authority
NZ
New Zealand
Prior art keywords
administering
nasal polyposis
antagonist
methods
treating nasal
Prior art date
Application number
NZ631118A
Other languages
English (en)
Inventor
Mannent Leda
A Gandhi Namita
Allen Radin
Pirozzi Gianluca
Evans Robert
Original Assignee
Regeneron Pharma
Sanofi Biotechnology
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Regeneron Pharma, Sanofi Biotechnology filed Critical Regeneron Pharma
Priority to NZ752224A priority Critical patent/NZ752224B2/en
Priority claimed from PCT/US2014/043440 external-priority patent/WO2014205365A1/en
Publication of NZ631118A publication Critical patent/NZ631118A/en

Links

Landscapes

  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
NZ631118A 2013-06-21 2014-06-20 Methods for treating nasal polyposis by administering an il-4r antagonist NZ631118A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
NZ752224A NZ752224B2 (en) 2013-06-21 2014-06-20 Methods for treating nasal polyposis by administering an il-4r antagonist

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361837912P 2013-06-21 2013-06-21
EP14305670 2014-05-07
PCT/US2014/043440 WO2014205365A1 (en) 2013-06-21 2014-06-20 Methods for treating nasal polyposis by administering an il-4r antagonist

Publications (1)

Publication Number Publication Date
NZ631118A true NZ631118A (en) 2019-05-31

Family

ID=66440559

Family Applications (1)

Application Number Title Priority Date Filing Date
NZ631118A NZ631118A (en) 2013-06-21 2014-06-20 Methods for treating nasal polyposis by administering an il-4r antagonist

Country Status (10)

Country Link
JP (3) JP6640977B2 (enExample)
DK (1) DK3010539T3 (enExample)
ES (1) ES2747630T3 (enExample)
HR (1) HRP20191709T1 (enExample)
HU (1) HUE046410T2 (enExample)
LT (1) LT3010539T (enExample)
NZ (1) NZ631118A (enExample)
PT (1) PT3010539T (enExample)
SG (1) SG10201912898XA (enExample)
TW (1) TWI707694B (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN116203244B (zh) * 2022-03-30 2025-06-27 首都医科大学附属北京同仁医院 一种无创诊断2型慢性鼻窦炎伴鼻息肉的试剂盒
CN116819076A (zh) * 2023-05-26 2023-09-29 首都医科大学附属北京同仁医院 一种预测或评估抗IL-4Rα单抗在治疗慢性鼻窦炎伴鼻息肉中疗效的生物标志物、应用和方法
CN117368487A (zh) * 2023-09-28 2024-01-09 首都医科大学附属北京同仁医院 一种利用局部IgE预测或评估奥马珠单抗在治疗复发性鼻息肉中疗效的方法和应用

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7608693B2 (en) * 2006-10-02 2009-10-27 Regeneron Pharmaceuticals, Inc. High affinity human antibodies to human IL-4 receptor
EP2414520A2 (en) * 2009-03-31 2012-02-08 Altair Therapeutics, Inc. Methods of modulating an immune response to a viral infection
UA111731C2 (uk) * 2010-10-06 2016-06-10 Рідженерон Фармасьютікалз, Інк. Стабілізована композиція, яка містить антитіло до рецептора інтерлейкіну-4 (іl-4r), варіанти
KR20160024916A (ko) * 2013-06-21 2016-03-07 사노피 바이오테크놀로지 Il-4r 길항제를 투여함에 의한 비용종증의 치료 방법

Also Published As

Publication number Publication date
TWI707694B (zh) 2020-10-21
SG10201912898XA (en) 2020-02-27
LT3010539T (lt) 2019-10-10
ES2747630T3 (es) 2020-03-11
HUE046410T2 (hu) 2020-03-30
JP2019069987A (ja) 2019-05-09
JP6640977B2 (ja) 2020-02-05
JP2020073525A (ja) 2020-05-14
TW201940193A (zh) 2019-10-16
NZ752224A (en) 2020-11-27
HRP20191709T1 (hr) 2019-12-13
PT3010539T (pt) 2019-10-14
JP2021138743A (ja) 2021-09-16
JP6898421B2 (ja) 2021-07-07
DK3010539T3 (da) 2019-10-21

Similar Documents

Publication Publication Date Title
AU2014284235B2 (en) Methods for treating nasal polyposis by administering an IL-4R antagonist
NZ706377A (en) Il-6 antagonists and uses thereof
AU2018253544A1 (en) Methods for treating or preventing asthma by administering an IL-4R antagonist
CA2967602C (en) METHODS OF TREATMENT OF CHRONIC SINUSITIS WITH NASAL POLYPOSIS BY ADMINISTRATION OF AN IL-4R ANTAGONIST
PH12014500089A1 (en) Antibodies that bind to ox40 and their uses
PH12013502201A1 (en) Anti-b7-h3 antibody
PH12015500390A1 (en) Antibodies and vaccines for use in treating ror1 cancers and inhibiting metastasis
CA2813849C (en) Secukinumab for use in the treatment of ankylosing spondylitis
TN2014000120A1 (en) Cd27l antigen binding proteins
PH12015502293A1 (en) Bispecific antibodies specific for fap and dr5, antibodies specific for dr5 and methods of use
MX341076B (es) Formulaciones estables de anticuerpos para el receptor humano pd-1 de meurte programada y tratamientos relacionados.
TN2015000247A1 (en) Bcma antigen binding proteins
PH12015501505B1 (en) Antibodies that bind to tl1a and their uses
PH12014500932A1 (en) Antibodies specific for trop-2 and their uses
PH12014501783B1 (en) Anti-lipoarabinomannan antibody and immunoassay for acid-fast bacillary infection using the antibody
MX2013011706A (es) Proteinas novedosas de enlace a antigeno.
MY163953A (en) Methods of inhibiting tumor growth by antagonizing il-6 receptor
CY1122132T1 (el) Μεθοδοι για τη μειωση των ρυθμων εξαρσης του ασθματος με χρηση μπενραλιζουμαμπης
NZ629553A (en) Anti-big-endothelin-1 (big-et-1) antibodies and uses thereof
NZ630864A (en) Use of semaphorin-4d binding molecules to promote neurogenesis following stroke
PH12015500751A1 (en) Anti-her3/her4 antigen binding proteins binding to the beta-hairpin of her3 and beta-hairpin of her4
MY184189A (en) Methods of treating nail and scalp psoriasis
MX2015005928A (es) Metodos para tratar el cancer de ovario con antagonistas de dll4.
NZ631118A (en) Methods for treating nasal polyposis by administering an il-4r antagonist
MX2016014726A (es) Proteinas de union al antigeno her1 que se unen a la beta-horquilla de her1.

Legal Events

Date Code Title Description
ASS Change of ownership

Owner name: REGENERON PHARMACEUTICALS, INC., US

Effective date: 20161201

Owner name: SANOFI BIOTECHNOLOGY, FR

Effective date: 20161201

PSEA Patent sealed
RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 3 YEARS UNTIL 20 JUN 2021 BY WATERMARK INTELLECTUAL PROPERTY PTY LTD.

Effective date: 20190911

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 20 JUN 2022 BY CPA GLOBAL

Effective date: 20210506

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 20 JUN 2023 BY CPA GLOBAL

Effective date: 20220505

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 20 JUN 2024 BY CPA GLOBAL

Effective date: 20230504

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 20 JUN 2025 BY ABHISHEK KUMAR - CPA-PTO PAYMENTS

Effective date: 20240509

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 20 JUN 2026 BY ABHISHEK KUMAR - CPA-PTO PAYMENTS

Effective date: 20250508